Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation
Science Advances · 16.01.2026 · 12 (3)
DOI: 10.1126/sciadv.aea9892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 16.01.2026. Verfasst von Bo Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, PKU International Cancer Institute, Peking University Health…. Hauptthemen laut MEDLINE: Breast Neoplasms, Enhancer of Zeste Homolog 2 Protein, Crotonates, Coenzyme A Ligases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Michigan Medicine-PKUHSC Joint Institute for Translational and Clinical Research, National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Crotonate, a short-chain fatty acid, generates protein crotonylation. However, the role of crotonate in cancer progression is unknown. Here, we present a crotonate–crotonyl–coenzyme A (CoA)–enhancer of zeste homolog 2 (EZH2) crotonylation cascade blocking breast cancer growth and metastasis. We demonstrated that crotonate promotes EZH2 degradation via crotonyl-CoA–mediated crotonylation at Lys 348 in EZH2 (EZH2-K348cr). EZH2-K348cr leads to reduced genome-wide H3K27me3 (trimethylation of lysine-27 on histone-3) occupancy. Crotonate metabolizes to crotonyl-CoA by ACSS2 (acyl-CoA synthetase 2), and then, acyltransferase p300 catalyzes crotonyl-CoA and generates EZH2-K348cr. Crotonylated EZH2 triggers EZH2 ubiquitination and degradation. Administration of crotonate markedly inhibits breast cancer cell growth and metastasis via a crotonate-crotonyl-CoA-EZH2-K348cr cascade. In comparison, crotonate showed better blocking effect than EZH2 inhibitor tazemetostat in suppressing breast cancer metastasis. The combination of crotonate and anti-PD-L1 (programmed cell death ligand 1) antibody enhances responses of breast cancer cells to immunotherapy. Together, our findings indicate that crotonate is a promising anticancer drug candidate that suppresses breast cancer growth and metastasis by specifically inducing EZH2 degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, PKU International Cancer Institute, Peking University Health Science Center, Beijing 100191, China.
- Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China.
ORCID-Profile: Bo Liu, Yu Yu, Hongquan Zhang
Förderung
- Michigan Medicine-PKUHSC Joint Institute for Translational and Clinical Research
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Liu, B., Duan, X., Wang, G., Tang, Y., Zhou, K., Zhang, J., Yu, Y., & Zhang, H. (2026). Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation. Science Advances, 12(3). https://doi.org/10.1126/sciadv.aea9892
Vancouver
Liu B, Duan X, Wang G, Tang Y, Zhou K, Zhang J, et al. Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation. Science Advances. 2026;12(3). doi:10.1126/sciadv.aea9892
BibTeX
@article{Liu2026,
author = {Liu, Bo and Duan, Xinwei and Wang, Ge and Tang, Youzhi and Zhou, Kunhao and Zhang, Jing and Yu, Yu and Zhang, Hongquan},
title = {Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {3},
doi = {10.1126/sciadv.aea9892}
}
EUVIMED